High dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis

BACKGROUND: Ursodeoxycholic acid (UDCA) in a dose of 28–30 mg/kg/day increases the likelihood of clinical deterioration of primary sclerosing cholangitis (PSC) patients. AIM: Our aim was to compare the risk of adverse clinical endpoints in patients with varying disease status. METHODS: We reviewed r...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς: Imam, Mohamad H., Sinakos, Emmanouil, Gossard, Andrea A., Kowdley, Kris V., Luketic, Velimir A. C., Harrison, M. Edwyn, McCashland, Timothy, Befeler, Alex S., Harnois, Denise, Jorgensen, Roberta, Petz, Jan, Keach, Jill, DeCook, Alisha C., Enders, Felicity, Lindor, Keith D.
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: 2011
Θέματα:
Article
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3752281/
https://ncbi.nlm.nih.gov/pubmed/21957881
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2036.2011.04863.x
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια